Quantification of Choline- and Ethanolamine-containing Metabolites in Human Prostate Tissues Using 1H HR-MAS Total Correlation Spectroscopy
Overview
Authors
Affiliations
A fast and quantitative 2D high-resolution magic angle spinning (HR-MAS) total correlation spectroscopy (TOCSY) experiment was developed to resolve and quantify the choline- and ethanolamine-containing metabolites in human prostate tissues in approximately 1 hr prior to pathologic analysis. At a 40-ms mixing time, magnetization transfer efficiency constants were empirically determined in solution and used to calculate metabolite concentrations in tissue. Phosphocholine (PC) was observed in 11/15 (73%) cancer tissues but only 6/32 (19%) benign tissues. PC was significantly higher (0.39 +/- 0.40 mmol/kg vs. 0.02 +/- 0.07 mmol/kg, z = 3.5), while ethanolamine (Eth) was significantly lower in cancer versus benign prostate tissues (1.0 +/- 0.8 mmol/kg vs. 2.3 +/- 1.9 mmol/kg, z = 3.3). Glycerophosphocholine (GPC) (0.57 +/- 0.87 mmol/kg vs. 0.29 +/- 0.26 mmol/kg, z = 1.2), phosphoethanolamine (PE) (4.4 +/- 2.2 mmol/kg vs. 3.4 +/- 2.6 mmol/kg, z = 1.4), and glycerophosphoethanolamine (GPE) (0.54 +/- 0.82 mmol/kg vs. 0.15 +/- 0.15 mmol/kg, z = 1.8) were higher in cancer versus benign prostate tissues. The ratios of PC/GPC (3.5 +/- 4.5 vs. 0.32 +/- 1.4, z = 2.6), PC/PE (0.08 +/- 0.08 vs. 0.01 +/- 0.03, z = 3.5), PE/Eth (16 +/- 22 vs. 2.2 +/- 2.0, z = 2.4), and GPE/Eth (0.41 +/- 0.51 vs. 0.06 +/- 0.06, z = 2.6) were also significantly higher in cancer versus benign tissues. All samples were pathologically interpretable following HR-MAS analysis; however, degradation experiments showed that PC, GPC, PE, and GPE decreased 7.7 +/- 2.2%, while Cho+mI and Eth increased 18% in 1 hr at 1 degrees C and a 2250 Hz spin rate.
Metabolomic profiling of human bladder tissue extracts.
Ossolinski K, Ruman T, Copie V, Tripet B, Kolodziej A, Plaza-Altamer A Metabolomics. 2024; 20(1):14.
PMID: 38267657 DOI: 10.1007/s11306-023-02076-w.
Emerging Hallmarks of Metabolic Reprogramming in Prostate Cancer.
Lasorsa F, di Meo N, Rutigliano M, Ferro M, Terracciano D, Tataru O Int J Mol Sci. 2023; 24(2).
PMID: 36674430 PMC: 9863674. DOI: 10.3390/ijms24020910.
Delkov D, Yoanidu L, Tomov D, Stoyanova R, Dechev I, Uzunova Y Turk J Med Sci. 2022; 52(3):699-706.
PMID: 36326306 PMC: 10390161. DOI: 10.55730/1300-0144.5363.
The Integration of Metabolomics with Other Omics: Insights into Understanding Prostate Cancer.
Resurreccion E, Fong K Metabolites. 2022; 12(6).
PMID: 35736421 PMC: 9230859. DOI: 10.3390/metabo12060488.
Steiner A, Schmidt S, Fellmann C, Nowak J, Wu C, Feldman A Cancers (Basel). 2022; 14(9).
PMID: 35565290 PMC: 9103328. DOI: 10.3390/cancers14092162.